What is Leerink Partnrs’ Forecast for AXSM FY2025 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Stock analysts at Leerink Partnrs dropped their FY2025 earnings estimates for shares of Axsome Therapeutics in a note issued to investors on Monday, February 10th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of ($4.60) per share for the year, down from their prior forecast of ($4.30). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.70) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ FY2026 earnings at ($0.40) EPS.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The firm had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. During the same quarter in the previous year, the business posted ($1.32) earnings per share.

Other equities research analysts also recently issued reports about the company. Deutsche Bank Aktiengesellschaft initiated coverage on Axsome Therapeutics in a report on Tuesday. They set a “buy” rating and a $176.00 target price for the company. William Blair reaffirmed an “outperform” rating on shares of Axsome Therapeutics in a research note on Friday, January 24th. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 target price on shares of Axsome Therapeutics in a report on Monday. Robert W. Baird boosted their price target on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Axsome Therapeutics in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $147.13.

Axsome Therapeutics Price Performance

AXSM opened at $131.55 on Thursday. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The business has a fifty day simple moving average of $96.55 and a 200-day simple moving average of $92.67. Axsome Therapeutics has a fifty-two week low of $64.11 and a fifty-two week high of $134.18.

Institutional Trading of Axsome Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Assetmark Inc. purchased a new position in Axsome Therapeutics in the fourth quarter valued at about $52,000. R Squared Ltd acquired a new stake in shares of Axsome Therapeutics during the 4th quarter valued at about $64,000. KBC Group NV lifted its holdings in shares of Axsome Therapeutics by 40.5% during the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after buying an additional 385 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Axsome Therapeutics by 22.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after buying an additional 318 shares in the last quarter. Finally, Moors & Cabot Inc. acquired a new position in Axsome Therapeutics in the third quarter worth approximately $200,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.